Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatmen...
Saved in:
Published in | Leukemia Vol. 25; no. 5; pp. 749 - 760 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article Conference Proceeding |
Language | English |
Published |
London
Nature Publishing Group UK
01.05.2011
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma. |
---|---|
Bibliography: | ObjectType-News-1 content type line 25 ObjectType-Feature-4 ObjectType-Conference-2 SourceType-Conference Papers & Proceedings-1 ObjectType-Article-3 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 0887-6924 1476-5551 |
DOI: | 10.1038/leu.2011.3 |